menu
    • menu
    [{"orgOrder":0,"company":"TRexBio","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"TRB-051","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"TRexBio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"TRexBio \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"TRexBio \/ Polaris Partners"},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"TRB-051","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Eli Lilly"},{"orgOrder":0,"company":"TRexBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"TRB-061","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"TRexBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TRexBio \/ Not Applicable"},{"orgOrder":0,"company":"TRexBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"TRexBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"TRexBio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"TRB-051","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Eli Lilly"},{"orgOrder":0,"company":"TRexBio","sponsor":"Delos Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"TRB-061","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"TRexBio","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"TRexBio \/ Delos Capital","highestDevelopmentStatusID":"5","companyTruncated":"TRexBio \/ Delos Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by TRexBio

    Menu

    TRexBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRB-061

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Delos Capital

                            Deal Size : $84.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            TRexBio Secures $84M Series B To Advance Immunology Pipeline

                            Details : The proceeds will be used to advance TRexBio’s TRB-061, a purpose-engineered TNFR2 agonist, in patients with immune mediated diseases including atopic dermatitis and ulcerative colitis.

                            Product Name : TRB-061

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : TRB-061

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Delos Capital

                            Deal Size : $84.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRB-051

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : $1,155.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TRexBio Announces Lilly has Initiated Phase 1 Study for Autoimmune Diseases

                            Details : Collaboration leveraged TRexBio’s Deep Biology Platform, which includes the TRB-051 program, is being evaluated in the early-stage clinical trial studies for autoimmune and inflammatory diseases.

                            Product Name : TRB-051

                            Product Type : Large molecule

                            Upfront Cash : $55.0 million

                            June 26, 2024

                            Lead Product(s) : TRB-051

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : $1,155.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TRexBio Announces Option Exercise Under Immunology Discovery Collaboration

                            Details : Johnson & Johnson has exercised an exclusive license option to develop and commercialize a novel target addressing immune-mediated diseases arising from a collaboration on unmet immune needs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRB-061

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Dise...

                            Details : TRB-061, an agonist targeting TNF receptor 2 (TNFR2). TRB-061 expands regulatory T cells (Tregs) to restore homeostasis in the tissue at the site of inflammation.

                            Product Name : TRB-061

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 14, 2023

                            Lead Product(s) : TRB-061

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRB-051

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Eli Lilly

                            Deal Size : $1,155.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies ...

                            Details : Collaboration leverages TRexBio’s Deep Biology platform, which mapsTreg behavior in human tissue to identify and target immune-regulatory pathways. Programs that have been identified and characterized leveraging TRex’s Deep Biology platform are TRB-0...

                            Product Name : TRB-051

                            Product Type : Large molecule

                            Upfront Cash : $55.0 million

                            January 09, 2023

                            Lead Product(s) : TRB-051

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Eli Lilly

                            Deal Size : $1,155.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            TRexBio

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRB-051

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Polaris Partners

                            Deal Size : $26.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Medi...

                            Details : Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in diseases, including its lead asset TRB-051.

                            Product Name : TRB-051

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 08, 2022

                            Lead Product(s) : TRB-051

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Polaris Partners

                            Deal Size : $26.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth